Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Grand Pharmaceutical Group Limited ( (HK:0512) ) is now available.
Grand Pharmaceutical Group has reported that its radionuclide-drug conjugate TLX591-CDx, marketed globally as Illuccix for prostate cancer diagnosis, has successfully met the primary endpoint in a Phase III clinical trial in China, demonstrating high positive predictive value across multiple metastatic sites and at very low PSA levels in patients with biochemical recurrence. The study also showed that TLX591-CDx imaging led to changes in treatment plans for more than two-thirds of participants, underlining its potential to materially influence clinical decision-making, while the approval to launch an international multi-centre Phase III trial in China for companion therapeutic candidate TLX591 strengthens the group’s position in prostate cancer theranostics and enhances its competitive standing in the fast-growing nuclear medicine segment.
The most recent analyst rating on (HK:0512) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a Bermuda-incorporated healthcare company with a strong focus on nuclear medicine-based anti-tumor diagnosis and treatment. Through a strategic partnership with Telix Pharmaceuticals, it holds exclusive rights in Greater China to multiple innovative radionuclide-drug conjugate (RDC) products, including TLX591, TLX591-CDx and TLX250-CDx. The group has built an integrated global nuclear medicine value chain spanning R&D, production, distribution and sales, supported by R&D centers in Boston and Chengdu, manufacturing facilities in Boston, Frankfurt, Singapore and Chengdu, and a sales network covering more than 50 countries and regions, with over 900 employees worldwide.
Average Trading Volume: 6,362,531
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.07B
See more data about 0512 stock on TipRanks’ Stock Analysis page.